Controversies in prostate cancer care: Real-world management of patients with mHSPC

Learning objective:         

After watching this broadcast, participants should be able to:

• Evaluate the added role of chemotherapy in individual patients with mHSPC, in the context of hormonal therapies
• Apply the evidence and guidelines to the management of oligorecurrent disease, including local and systemic therapy

Scientific Committee:

• Steven Joniau (Belgium)
• Gunhild von Amsberg (Germany)

Faculty:

• Juan Gómez Rivas (Spain)
• Pierre Blanchard (France)

We are pleased to announce that our courses have been independently evaluated for Continuing Professional Development purposes by The CPD Certification Service. This means our courses comply with universally accepted principles of Continual Professional Development (CPD) and have been structured to meet the criteria of personal development plans.